Establishment Labs Third Quarter 2026 Financial Results - ESTABLISHMENT LABS HOLDINGS INC

Financial Performance:

• Q3 2026 revenue reached $72 million, a 33.9% year-over-year increase.
• U.S. revenue surged 119% to $26 million (36.1% of total), while OUS revenue grew 9.7% to $46 million.
• Adjusted EBITDA improved to $6.4 million (8.9% margin) from $1.2 million (2.2% margin) in the prior year.
• Adjusted gross margin was 70.8%, up 70 basis points year-over-year, driven by favorable U.S. and minimally invasive product mix.
• GAAP gross margin was 69.1% after excluding $1.3 million in restructuring-related inventory charges.
• The company achieved its first-ever positive free cash flow of $5.1 million, with operating cash flow of $7.7 million.
• Cash and cash equivalents ended the quarter at $75.8 million; debt service includes a payment-in-kind provision saving >$5 million in quarterly cash interest.
• Adjusted operating expenses were $49.6 million, reflecting 880 basis points of operating leverage improvement compared to the prior year.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to >$274 million (previously $269M–$271M).
• Full-year 2026 adjusted gross margin expected to be approximately 70.7%; adjusted operating expenses guidance remains $195M–$200M.
• Projected full-year 2026 adjusted EBITDA to be positive; full-year 2027 revenue growth targeted at 25%.
• Minimally invasive revenue guidance raised to >$40 million for 2026 (previously >$35M).
• Management expects 2027 gross margin expansion of 50–100 basis points driven by geographic and product mix improvements.
• Reconstruction product approval anticipated in late 2026 or Q1 2027, with revenue contribution expected in the back half of 2027.

Business Segments and Product Lines:

• Minimally invasive platform generated $9 million in Q3 (124% YoY growth), representing 15% of YTD revenue; U.S. accounts for nearly half of this segment.
• U.S. account base reached 2,100; Motiva represents ~43% of augmentation procedures among reporting surgeons, with 85% retention rate in Q2/Q3.
• "Preserve" product launched 400+ surgeons trained by Q3 end, projected to reach 500 by year-end; 22% of trained surgeons shifted augmentation volume to Preserve.
• FDA approved additional Motiva implant sizes (down to 105 cc) in October 2026, expected commercially available before year-end.
• MIA and Preserve global size expansions announced: MIA up to 300 cc, Preserve up to 380 cc.
• Motiva Flora Tissue Expander available in 350+ facilities nationwide (14% growth during Q3).
• OUS direct markets grew 16% YoY, with strong performance in Italy, UK, and Germany; distributor markets (60% of OUS revenue) driven by Asia Pacific.

Market and Competitive Landscape:

• U.S. breast augmentation procedures grew 11% from 2024–2025; Establishment Labs attributes growth to product innovation and market expansion.
• Motiva estimated at ~30% share of the U.S. augmentation market as of September 2026.
• Consumer and surgeon awareness rising: Preserve won Allure Best of Beauty Award; featured in Forbes as "Rolls-Royce of breast augmentation."
• "Ballerina" or "yoga" breast trends driving demand for smaller, natural-looking implants.
• Industry data indicates surgeons adopting Motiva and Preserve are seeing patients previously not considering augmentation, particularly post-partum patients.
• OUS markets generally stable despite macro headwinds in the Middle East; direct market leadership optimizations driving double-digit growth.

Risks and Challenges:

• Seasonality: Q3 typically the softest quarter; sequential minimally invasive revenue dip attributed to normal summer seasonality in OUS direct markets.
• Regulatory timeline: FDA reconstruction approval process involves VAC committees with 3–6 month timelines per facility; timing remains a key variable.
• Distributor mix variability: OUS distributor sales represented 60% vs. planned 50%, slightly lowering overall gross margin percentage despite higher gross profit dollars.
• Macroeconomic and geopolitical risks: Specific impact noted in the Middle East due to ongoing conflict affecting orders.
• Inflationary pressure on costs: Addressed via the NuCil strategic agreement with pricing aligned to inflation trends.

Management Commentary and Tone:

• Tone was highly confident, emphasizing the achievement of positive free cash flow as a major milestone and proof of financial model scalability.
• Management emphasized a strategic shift from account acquisition to driving utilization among existing 2,100 U.S. accounts.
• Peter Caldini (CEO) highlighted innovation as the primary driver for expanding the total market, not just gaining share.
• Sondra Harris (CFO) noted significant operating leverage with a nearly 900 basis point reduction in operating expense percentage.
• Management reaffirmed commitment to hiring sales reps (up to 55) and strengthening leadership to support U.S. expansion and reconstruction readiness.

Analyst Questions and Answers:

• International Growth: Management confirmed stability in OUS markets (excluding Middle East) and credited direct market leadership changes and distributor optimization for 16% direct growth.
• Minimally Invasive Sequential Dip: Q3 QoQ revenue dip explained solely by seasonal weakness in European direct markets, not demand softness; YoY growth remains strong.
• U.S. Utilization Strategy: Focus on increasing average orders per account via sales force expansion and marketing; 43% current utilization seen as having significant runway.
• 2027 Margins: Expected 50–100 bps margin expansion in 2027 driven by higher-margin U.S. mix (>35% of revenue) and minimally invasive adoption (>15%).
• Reconstruction Pipeline: Commercial infrastructure being built now; FLORA is already in 350+ facilities, serving as a wedge to gain VAC committee access for implants.
• NuCil Agreement: New silicone supply contract terms are "business as usual," consistent with prior agreements regarding volume tiers and inflation adjustments.

Other Key Points:

• Strategic supply agreement signed with NuCil to secure long-term silicone supply and scale production.
• "Motiva" is becoming an entry point for new surgeons in Europe, with nearly half of new accounts starting with minimally invasive products.
• Restructuring and litigation costs were excluded from adjusted operating expenses; GAAP net loss improved to $10.7 million ($0.35/share) vs $11.1 million ($0.38/share) prior year.
• Company expects to maintain positive free cash flow in fiscal 2027 following the Q3 2026 milestone.